PRCT DEADLINE: SueWallSt Reminds PROCEPT BIOROBOTICS CORPORATION Investors of Upcoming Securities Class Action Deadline

PROCEPT analyst reaction and Wall Street securities concerns focus on allegations that investors relied on handpiece sales metrics while actual procedure demand lagged, culminating in a more than 75% PRCT decline from the Class Period high.

NEW YORK, Aug. 20, 2026 /PRNewswire/ -- SueWallSt alerts investors in PROCEPT BioRobotics Corporation (NASDAQ: PRCT) that a securities class action has been filed on behalf of shareholders who purchased securities between February 28, 2024 and February 25, 2026.

PRCT shares declined more than 75%, falling by approximately $75.00 per share from a Class Period high of about $100.00 to less than $25.00. The February 25, 2026 disclosure included actual procedure data, an alleged 8% to 16% quarterly handpiece-to-procedure gap, more than 10,000 excess field handpieces, a 30% sequential contraction in unit sales, and a September 22, 2026 lead plaintiff deadline.

Wall Street questioning sharpened after PROCEPT disclosed that actual procedures had not previously been reported and that discounted handpiece orders had allegedly caused unit sales to exceed procedure demand.

The complaint recounts that a Truist Securities analyst asked about the health of underlying procedure demand in light of prior explanations tied to seemingly transient externalities.

As alleged, the Company had previously attributed revenue fluctuations to outside issues such as saline shortages while assuring investors that handpiece sales and procedures remained relatively consistent.

The securities action claims that analyst scrutiny later centered on whether reported handpiece growth had overstated recurring demand.

Analysts had focused on utilization because PROCEPT's valuation depended heavily on recurring handpiece sales tied to AquaBeam procedures. The complaint alleges investors were not given actual procedure data until February 25, 2026.

Wall Street questioning after the disclosure addressed whether prior explanations understated inventory overstocking risks.

The Company disclosed that handpiece sales had exceeded procedures by 8% to 16% every quarter since Q1 2023.

Unit sales allegedly contracted from approximately 13,200 in Q3 2025 to approximately 9,400 in Q4 2025.

The action asserts that analysts were evaluating a core investor assumption: whether handpiece revenue reflected real procedure growth or customer inventory buildup.

Because handpieces sold for approximately $3,200 each and comprised a rising share of revenue, even small distortions in demand signals could allegedly affect valuation.

Learn more about the case or call (888) SueWallSt.